Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes paralysis of limb, swallowing, and breathing muscles. Riluzole, the Food and Drug Administration-approved drug for ALS, provides minimal benefit, prolonging patient life by only 2–3 months. Previous stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sungha, Kim, Jae Kyoun, Son, Mi Ju, Kim, Dongwoung, Song, Bongkeun, Son, Ilhong, Kang, Hyung Won, Lee, Jongdeok, Kim, Sungchul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899359/
https://www.ncbi.nlm.nih.gov/pubmed/29653550
http://dx.doi.org/10.1186/s13063-018-2557-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899359/
https://www.ncbi.nlm.nih.gov/pubmed/29653550
http://dx.doi.org/10.1186/s13063-018-2557-z

Ejemplares similares